ARE WORMS THE KEY TO THE HUMAN GENOME?

December 8, 2000

SCIENCE & ENGINEERING NEWS

San Francisco, CALIF. — Naomi Aoki reports for the Boston Globe that it was December 1998 when scientists said they had sequenced the genome of a tiny earthworm called the nematode as a test run for mapping the human genome.

Peter Hansen and Petra Krauledat remember it well. The husband-and-wife team had just built a machine for a small Cambridge company to study the creatures. And they had lost a lot of money on the contract.

Then, suddenly, this obscure little worm was propelled to international scientific celebrity. Its genetic makeup, it turned out, was remarkably similar to that of humans. It could help scientists understand the role of certain genes and develop drugs to treat diseases such as Alzheimer’s and diabetes.

“In 1998, nobody had even heard of this worm other than some nerdy biologists,” said Petra Krauledat, a biologist herself and president of Union Biometrica Inc. “By mid-1999, every drug company had a program using these nematodes.”

And the machine that Hansen and Krauledat had considered a financial loss had suddenly become the key to unlocking the nematode’s potential – and their company’s.

The machine could do in a few weeks what took scientists peering through microscopes more than a year to do. It could test tens of thousands of drug candidates on hundreds of thousands of living nematodes, identifying those that work. And, eventually, Hansen and Krauledat said, it could drastically shrink the time, risks and cost of drug discovery for humans.

“One of the lessons of the human genome project is that automation is essential to basic life-science research,” said Hansen, a physicist and Union Biometrica’s chairman and chief technology officer. “The day of the white- coated laboratory researcher is gone.”

Drug discovery is an expensive and risky business. Out of 10,000 promising compounds, only one will make it to market. It will take an average of 15 years and $300 million to get there. And more than half of that money will be spent before the drug even reaches human clinical trials.

The very survival of pharmaceutical and biotechnology companies depends on improving those odds. As medicine advances, drug companies are tackling more complex and elusive diseases. They are pouring more money into research, meaning they must also deliver more drugs to stay financially healthy.

At the same time, the public outcry over drug pricing is increasing, forcing companies to explore more cost-effective and less risky ways of developing drugs. The crush of data streaming out of genomic research is also demanding faster and more systematic approaches to drug discovery.

Faced with these challenges, drug and biotech companies are turning to robotics, optics and high-performance computing to speed the pace of drug discovery.

Robots stack, move and place trays of cells onto machines that record the cells’ reactions to various doses of drugs. Computers systematically match libraries of drug compounds with models of genes. Huge databases of genetic information scan other databases for similar genes.

But the automation typically stops when drug compounds leave the research bench to be tested on mice or other animals. Scientists genetically alter the mice to mimic human diseases, give them the test drug, observe them and later autopsy the mice to determine if the drug had any effect.

The process is time-consuming, labor-intensive and costly. It can take months for researchers to study a reaction in the mice. Often, the discoveries are made only after killing and dissecting the mice to study their biological responses to the disease and the drug.

That’s why pharmaceutical companies and the scientific community greeted with open arms the surprise discovery that nematodes and humans were genetically similar.

Compared to mice, nematodes are cheap and easy to study. The worms are transparent, allowing researchers to track a gene inserted into a nematode under a microscope by adding a fluorescent protein to the gene. And if a drug turns off the gene – a sign that the drug is working – the glow disappears.

The worms also reproduce quickly, making hundreds of exact copies of themselves in a few days. And since they are tiny (one-millimeter long as adults), they can be easily stored in small petri dishes or test tubes.

But there are some drawbacks. Their size and tendency to wiggle make them tricky to catch. Scientists peer through microscopes, grabbing the worms with a sliver of platinum wire. The work is tedious and tiresome. And although faster than testing on mice, it takes days to analyze 1,000 nematodes.

By automating the process, however, Hansen and Krauledat have shrunk days’ worth of work into a single minute. And in doing so, they invented the only automated system of testing living organisms. The machine also can be adjusted to test other small, simple organisms such as fruit flies and zebra fish.

Called the COPAS Technology Platform, the automated testing system feeds the creatures one by one into a tube and through a scanning system that reads the fluorescent genes. The more the worm or fruit fly glows, the more active the disease.

The scanner relays the information to the computer, which plots the worm on an on-screen image according to its age and level of disease. The computer then instructs the machine to sort the worm accordingly.

The COPAS system does all this at the rate of 100 nematodes per second. In a rapid-fire fashion, researchers can test thousands of drug compounds and spot the ones that dim the glowing genes. They can also weed out compounds that seem to have toxic side effects.

Historically, when researchers have begun testing a drug on a mouse, they’ve known very little about the drug. It looks promising when tested against tissue samples or single cells in a test tube or petri dish. But they have no information about how it might work in a living organism.

Testing on nematodes or other simple organisms can help narrow down the candidates that move through the pipeline, reducing the risks and costs of failing later in the process.

The testing machine costs between $200,000 and $700,000, depending on the complexity of the system. So far, companies that have bought it are using it as an intermediate testing stop between the lab and the mouse.

As the technology spreads, however, Hansen and Krauledat said it could be used to replace lab tests on cells and tissue samples, making testing on nematodes and other simple creatures the first and last step before testing on mice.

On average, Krauledat said, it now costs a company $200 million to get a drug from the idea stage to the first human clinical trial. Hansen and Krauledat said their technology can shrink that number to $50 million over the next five years.

Hansen and Krauledat said they haven’t advertised the machine or published their findings in scientific journals. Indeed, references to Union Biometrica are few and far between in the mainstream media. They’ve been too busy, they say, to worry about publicity.

Word of mouth, however, has brought some of the world’s largest pharmaceutical companies to their door. Among their customers are industry giants like AstraZeneca PLC, Aventis SA, Johnson & Johnson, Novartis AG, SmithKline Beecham, and Glaxo Wellcome PLC.

In May, after a decade of supporting the private company on revenue from their contract work, Hansen and Krauledat accepted $2 million in venture capital. It was time, they decided, to concentrate on developing and marketing their new technology without the distraction of scrambling for cash.

The Somerville, Mass., company will finish this year with $4 million in sales, a figure Hansen and Krauledat expect to double next year. With a backlog of 130 labs interested in the machine, they said, their biggest problem is hiring people to meet the demand.

“To find out what all these newly discovered genes do and how to make drugs that affect them is going to require new kinds of equipment and new ways of doing things,” Hansen said. “That’s what we’re really offering – new ways to study disease and discover drugs to treat those diseases.”

============================================================

Subscribe to HPCwire's Weekly Update!

Be the most informed person in the room! Stay ahead of the tech trends with industy updates delivered to you every week!

Cray, Fujitsu Both Bringing Fujitsu A64FX-based Supercomputers to Market in 2020

November 12, 2019

The number of top-tier HPC systems makers has shrunk due to a steady march of M&A activity, but there is increased diversity and choice of processing components with Intel Xeon, AMD Epyc, IBM Power, and Arm server ch Read more…

By Tiffany Trader

SIA Recognizes Robert Dennard with 2019 Noyce Award

November 12, 2019

If you don’t know what Dennard Scaling is, the chances are strong you don’t labor in electronics. Robert Dennard, longtime IBM researcher, inventor of the DRAM and the fellow for whom Dennard Scaling was named, is th Read more…

By John Russell

Leveraging Exaflops Performance to Remediate Nuclear Waste

November 12, 2019

Nuclear waste storage sites are a subject of intense controversy and debate; nobody wants the radioactive remnants in their backyard. Now, a collaboration between Berkeley Lab, Pacific Northwest National University (PNNL Read more…

By Oliver Peckham

Using HPC and Machine Learning to Predict Traffic Congestion

November 12, 2019

Traffic congestion is a never-ending logic puzzle, dictated by commute patterns, but also by more stochastic accidents and similar disruptions. Traffic engineers struggle to model the traffic flow that occurs after accid Read more…

By Oliver Peckham

Mira Supercomputer Enables Cancer Research Breakthrough

November 11, 2019

Dynamic partial-wave spectroscopic (PWS) microscopy allows researchers to observe intracellular structures as small as 20 nanometers – smaller than those visible by optical microscopes – in three dimensions at a mill Read more…

By Staff report

AWS Solution Channel

Making High Performance Computing Affordable and Accessible for Small and Medium Businesses with HPC on AWS

High performance computing (HPC) brings a powerful set of tools to a broad range of industries, helping to drive innovation and boost revenue in finance, genomics, oil and gas extraction, and other fields. Read more…

IBM Accelerated Insights

IBM Adds Support for Ion Trap Quantum Technology to Qiskit

November 11, 2019

After years of percolating in the shadow of quantum computing research based on superconducting semiconductors – think IBM, Rigetti, Google, and D-Wave (quantum annealing) – ion trap technology is edging into the QC Read more…

By John Russell

Cray, Fujitsu Both Bringing Fujitsu A64FX-based Supercomputers to Market in 2020

November 12, 2019

The number of top-tier HPC systems makers has shrunk due to a steady march of M&A activity, but there is increased diversity and choice of processing compon Read more…

By Tiffany Trader

IBM Adds Support for Ion Trap Quantum Technology to Qiskit

November 11, 2019

After years of percolating in the shadow of quantum computing research based on superconducting semiconductors – think IBM, Rigetti, Google, and D-Wave (quant Read more…

By John Russell

Tackling HPC’s Memory and I/O Bottlenecks with On-Node, Non-Volatile RAM

November 8, 2019

On-node, non-volatile memory (NVRAM) is a game-changing technology that can remove many I/O and memory bottlenecks and provide a key enabler for exascale. Th Read more…

By Jan Rowell

MLPerf Releases First Inference Benchmark Results; Nvidia Touts its Showing

November 6, 2019

MLPerf.org, the young AI-benchmarking consortium, today issued the first round of results for its inference test suite. Among organizations with submissions wer Read more…

By John Russell

Azure Cloud First with AMD Epyc Rome Processors

November 6, 2019

At Ignite 2019 this week, Microsoft's Azure cloud team and AMD announced an expansion of their partnership that began in 2017 when Azure debuted Epyc-backed ins Read more…

By Tiffany Trader

Nvidia Launches Credit Card-Sized 21 TOPS Jetson System for Edge Devices

November 6, 2019

Nvidia has launched a new addition to its Jetson product line: a credit card-sized (70x45mm) form factor delivering up to 21 trillion operations/second (TOPS) o Read more…

By Doug Black

In Memoriam: Steve Tuecke, Globus Co-founder

November 4, 2019

HPCwire is deeply saddened to report that Steve Tuecke, longtime scientist at Argonne National Lab and University of Chicago, has passed away at age 52. Tuecke Read more…

By Tiffany Trader

Spending Spree: Hyperscalers Bought $57B of IT in 2018, $10B+ by Google – But Is Cloud on Horizon?

October 31, 2019

Hyperscalers are the masters of the IT universe, gravitational centers of increasing pull in the emerging age of data-driven compute and AI.  In the high-stake Read more…

By Doug Black

Supercomputer-Powered AI Tackles a Key Fusion Energy Challenge

August 7, 2019

Fusion energy is the Holy Grail of the energy world: low-radioactivity, low-waste, zero-carbon, high-output nuclear power that can run on hydrogen or lithium. T Read more…

By Oliver Peckham

Using AI to Solve One of the Most Prevailing Problems in CFD

October 17, 2019

How can artificial intelligence (AI) and high-performance computing (HPC) solve mesh generation, one of the most commonly referenced problems in computational engineering? A new study has set out to answer this question and create an industry-first AI-mesh application... Read more…

By James Sharpe

Cray Wins NNSA-Livermore ‘El Capitan’ Exascale Contract

August 13, 2019

Cray has won the bid to build the first exascale supercomputer for the National Nuclear Security Administration (NNSA) and Lawrence Livermore National Laborator Read more…

By Tiffany Trader

DARPA Looks to Propel Parallelism

September 4, 2019

As Moore’s law runs out of steam, new programming approaches are being pursued with the goal of greater hardware performance with less coding. The Defense Advanced Projects Research Agency is launching a new programming effort aimed at leveraging the benefits of massive distributed parallelism with less sweat. Read more…

By George Leopold

AMD Launches Epyc Rome, First 7nm CPU

August 8, 2019

From a gala event at the Palace of Fine Arts in San Francisco yesterday (Aug. 7), AMD launched its second-generation Epyc Rome x86 chips, based on its 7nm proce Read more…

By Tiffany Trader

D-Wave’s Path to 5000 Qubits; Google’s Quantum Supremacy Claim

September 24, 2019

On the heels of IBM’s quantum news last week come two more quantum items. D-Wave Systems today announced the name of its forthcoming 5000-qubit system, Advantage (yes the name choice isn’t serendipity), at its user conference being held this week in Newport, RI. Read more…

By John Russell

Ayar Labs to Demo Photonics Chiplet in FPGA Package at Hot Chips

August 19, 2019

Silicon startup Ayar Labs continues to gain momentum with its DARPA-backed optical chiplet technology that puts advanced electronics and optics on the same chip Read more…

By Tiffany Trader

Crystal Ball Gazing: IBM’s Vision for the Future of Computing

October 14, 2019

Dario Gil, IBM’s relatively new director of research, painted a intriguing portrait of the future of computing along with a rough idea of how IBM thinks we’ Read more…

By John Russell

Leading Solution Providers

ISC 2019 Virtual Booth Video Tour

CRAY
CRAY
DDN
DDN
DELL EMC
DELL EMC
GOOGLE
GOOGLE
ONE STOP SYSTEMS
ONE STOP SYSTEMS
PANASAS
PANASAS
VERNE GLOBAL
VERNE GLOBAL

Intel Confirms Retreat on Omni-Path

August 1, 2019

Intel Corp.’s plans to make a big splash in the network fabric market for linking HPC and other workloads has apparently belly-flopped. The chipmaker confirmed to us the outlines of an earlier report by the website CRN that it has jettisoned plans for a second-generation version of its Omni-Path interconnect... Read more…

By Staff report

Kubernetes, Containers and HPC

September 19, 2019

Software containers and Kubernetes are important tools for building, deploying, running and managing modern enterprise applications at scale and delivering enterprise software faster and more reliably to the end user — while using resources more efficiently and reducing costs. Read more…

By Daniel Gruber, Burak Yenier and Wolfgang Gentzsch, UberCloud

Dell Ramps Up HPC Testing of AMD Rome Processors

October 21, 2019

Dell Technologies is wading deeper into the AMD-based systems market with a growing evaluation program for the latest Epyc (Rome) microprocessors from AMD. In a Read more…

By John Russell

Intel Debuts Pohoiki Beach, Its 8M Neuron Neuromorphic Development System

July 17, 2019

Neuromorphic computing has received less fanfare of late than quantum computing whose mystery has captured public attention and which seems to have generated mo Read more…

By John Russell

Rise of NIH’s Biowulf Mirrors the Rise of Computational Biology

July 29, 2019

The story of NIH’s supercomputer Biowulf is fascinating, important, and in many ways representative of the transformation of life sciences and biomedical res Read more…

By John Russell

Xilinx vs. Intel: FPGA Market Leaders Launch Server Accelerator Cards

August 6, 2019

The two FPGA market leaders, Intel and Xilinx, both announced new accelerator cards this week designed to handle specialized, compute-intensive workloads and un Read more…

By Doug Black

When Dense Matrix Representations Beat Sparse

September 9, 2019

In our world filled with unintended consequences, it turns out that saving memory space to help deal with GPU limitations, knowing it introduces performance pen Read more…

By James Reinders

With the Help of HPC, Astronomers Prepare to Deflect a Real Asteroid

September 26, 2019

For years, NASA has been running simulations of asteroid impacts to understand the risks (and likelihoods) of asteroids colliding with Earth. Now, NASA and the European Space Agency (ESA) are preparing for the next, crucial step in planetary defense against asteroid impacts: physically deflecting a real asteroid. Read more…

By Oliver Peckham

  • arrow
  • Click Here for More Headlines
  • arrow
Do NOT follow this link or you will be banned from the site!
Share This